Receptor News and Research

RSS

New approach to regulate people's cholesterol levels

A discovery about how the body deals with the cholesterol contained within its dying cells has suggested an exciting new approach to control people's cholesterol levels - and thus their risk of developing heart disease.

19 Nov 2015

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics (OADs) combined with a GLP-1 receptor agonist do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this fixed combination offers an added benefit over the appropriate comparator therapy (ACT).

19 Nov 2015

Georgia State University researchers develop a method to better trace and treat cancer

A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed by Georgia State University researchers.

18 Nov 2015

Scientists develop potent compound that promotes wakefulness, remedies sleep disorder narcolepsy

Hiroshi Nagase, a Professor at the International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, collaborated with Masashi Yanagisawa (Professor / Director of WPI-IIIS) and successfully developed a potent compound that promotes wakefulness and remedies the sleep disorder narcolepsy in model animals.

18 Nov 2015

UCLA researchers find new way to reduce ascites with minimal side effects

Women who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen. The most common treatment for ascites is puncturing the abdomen and manually draining the fluid, which is painful and risky and must be repeated every few weeks.

18 Nov 2015

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Researchers at the UC Davis Comprehensive Cancer Center have shown that the microRNA, miR-124, reduced tumor growth and increased cell death in castration-resistant prostate cancer.

17 Nov 2015

Researchers identify genetic mutation associated with reckless drunken behavior

University of Helsinki researchers have identified a genetic mutation which renders carriers susceptible to particularly impulsive and reckless behaviour when drunk. More than one hundred thousand Finns carry this mutation.

17 Nov 2015

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Birmingham researchers identify how Salmonella infections can lead to life-threatening thrombosis

Researchers from the University of Birmingham have, for the first time, identified how Salmonella infections that have spread to our blood and organs can lead to life-threatening thrombosis.

17 Nov 2015

Researchers identify new target for novel immune-oncology treatments

By studying a type of immune cells, a team of researchers at the IRCM led by André Veillette, MD, identified the mechanism of action for a new target for novel immune-oncology treatments. Their discovery is published today in the print edition of the scientific journal the Journal of Experimental Medicine.

17 Nov 2015

Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition.

17 Nov 2015

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.

17 Nov 2015

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

14 Nov 2015

Different types of asthma respond differently to new experimental treatment

University of Queensland research into the effects of dust mite and cockroach allergens has found that different types of asthma respond differently to a new experimental treatment.

12 Nov 2015

Loyola and Notre Dame researchers report promising new approaches to treating cancer

Promising new approaches to treating cancer were reported during a recent meeting of researchers from Loyola University Chicago and the University of Notre Dame.

12 Nov 2015

Anavex reports safety and efficacy data of ANAVEX 2-73 Phase 2a trial in Alzheimer’s patients

On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s disease targeting sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.

11 Nov 2015

New findings reveal association between colorectal cancer and melanoma drug treatment

Veteran cancer reseacher Prof. Emeritus Alexander Levitzki of Hebrew University of Jerusalem says new findings show link between colorectal cancer and melanoma drug treatment knoqwn as "NT157" in two recently published studies in journal, "Ocogene."

10 Nov 2015

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

10 Nov 2015

Receptor News and Research

New approach to regulate people's cholesterol levels

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

Georgia State University researchers develop a method to better trace and treat cancer

Scientists develop potent compound that promotes wakefulness, remedies sleep disorder narcolepsy

UCLA researchers find new way to reduce ascites with minimal side effects

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Researchers identify genetic mutation associated with reckless drunken behavior

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Birmingham researchers identify how Salmonella infections can lead to life-threatening thrombosis

Researchers identify new target for novel immune-oncology treatments

Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Different types of asthma respond differently to new experimental treatment

Loyola and Notre Dame researchers report promising new approaches to treating cancer

Anavex reports safety and efficacy data of ANAVEX 2-73 Phase 2a trial in Alzheimer’s patients

New findings reveal association between colorectal cancer and melanoma drug treatment

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News